InnoCan Pharma's ROE % for the quarter that ended in Mar. 2026 was -71.99%. InnoCan Pharma's PB Ratio for the quarter that ended in Mar. 2026 was 4.28.
InnoCan Pharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -16.82%.
InnoCan Pharma ROE % Adjusted to Book Value Related Terms
InnoCan Pharma ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INNPF vs PG, CL, KVUE: ROE % Adjusted to Book Value Comparison
For the Household & Personal Products subindustry, InnoCan Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma ROE % Adjusted to Book Value vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -16.82% mean?
InnoCan Pharma (INNPF) has a ROE % Adjusted to Book Value of -16.82% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on InnoCan Pharma and its competitors.
Is InnoCan Pharma's ROE % Adjusted to Book Value too high?
InnoCan Pharma's current ROE % Adjusted to Book Value is -16.82%. Overall, InnoCan Pharma has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's ROE % Adjusted to Book Value compare to PG and CL?
InnoCan Pharma's ROE % Adjusted to Book Value of -16.82% can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Consumer Packaged Goods company?
A good ROE % Adjusted to Book Value depends on the Consumer Packaged Goods industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on InnoCan Pharma and its competitors. InnoCan Pharma's current ROE % Adjusted to Book Value is -16.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (INNPF) is currently considered Possible Value Trap. The stock's GF Value™ is $10.03, compared to a current price of $1.70 — trading 83.1% below its estimated fair value. The current ROE % Adjusted to Book Value is -16.82%. InnoCan Pharma's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For InnoCan Pharma (INNPF), the current ROE % Adjusted to Book Value is -16.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (INNPF) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of $1.70 is trading 83.1% below its estimated GF Value™ of $10.03.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for INNPF:
ROE % Adjusted to Book Value: -16.82%
GF Value™: $10.03 vs. price of $1.70 (83.1% below fair value)
No single metric tells the full story. See the INNPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
56GF Score
Get the complete analysis for INNPF
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INNPF has been successfully added to your 
